| Literature DB >> 33302885 |
Holly Tibble1,2, James Lay-Flurrie3, Aziz Sheikh4,5,6, Rob Horne5,7, Mehrdad A Mizani4,5, Athanasios Tsanas4,5.
Abstract
BACKGROUND: Records of medication prescriptions can be used in conjunction with pharmacy dispensing records to investigate the incidence of adherence, which is defined as observing the treatment plans agreed between a patient and their clinician. Using prescribing records alone fails to identify primary non-adherence; medications not being collected from the dispensary. Using dispensing records alone means that cases of conditions that resolve and/or treatments that are discontinued will be unaccounted for. While using a linked prescribing and dispensing dataset to measure medication non-adherence is optimal, this linkage is not routinely conducted. Furthermore, without a unique common event identifier, linkage between these two datasets is not straightforward.Entities:
Mesh:
Year: 2020 PMID: 33302885 PMCID: PMC7731758 DOI: 10.1186/s12874-020-01184-8
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Fig. 1Diagram representing the data linkage algorithm
Fig. 2Data Linkage Flow Diagram
Fig. 3Distributions of linkage weight points per variable, for candidates and final matches
Fig. 4Kaplan-Meier of the time to collecting prescriptions, censored at three weeks
Cox Proportional hazards model risk factors associated with time to collecting a prescribed medication
| Hazard Ratio (95% Confidence Interval) | Statistical significance ( | |
|---|---|---|
| Season | ||
| Spring | {reference} | |
| Summer | 0.967 (0.944–0.991) | 0.008 * |
| Autumn | 0.981 (0.958–1.005) | 0.123 |
| Winter | 1.003 (0.979–1.028) | 0.791 |
| Drug Class | ||
| SABA | 1.433 (1.387–1.479) | < 0.001 * |
| LABA | 0.938 (0.890–0.990) | 0.019 * |
| ICS | {reference} | |
| ICS + LABA | 1.067 (1.033–1.102) | < 0.001 * |
| Cromoglicate | 0.778 (0.389–1.558) | 0.479 |
| Immuno-suppressants | 1.244 (1.100–1.408) | < 0.001 * |
| LAMA | 1.349 (1.161–1.567) | < 0.001 * |
| LTRA | 1.350 (1.289–1.414) | < 0.001 * |
| Theophylline | 1.040 (0.897–1.205) | 0.604 |
| Oral steroids | 1.839 (1.743–1.940) | < 0.001 * |
| Previously unclaimed medications | ||
| Low tertile | {reference} | |
| Mid tertile | 0.565 (0.553–0.577) | < 0.001 * |
| High tertile | 0.198 (0.193–0.204) | < 0.001 * |
| Quantity of doses prescribed | 1.000 ** (1.000–1.000) | < 0.001 * |
Statistically significant variables (using a threshold of p = 0.05) are denoted by a star (*)
** Coefficient 0.9999 to four decimal places, and therefore lower than the reference value
String Search Keywords by Medication and Drug Class Keyword Categories
| Drug Class Keyword | Medication Keyword | String Search Keywords |
|---|---|---|
| SABA | SALBUTAMOL | “SALBUTAMOL”, “ALBUTEROL”, |
| SABA | BAMBUTEROL | “BAMBUTEROL”, |
| LABA | FORMOTEROL | “FORMOTEROL”, |
| LABA | SALMETEROL | “SALMETEROL”, |
| LABA | TERBUTALINE | “TERBUTALINE”, |
| LABA | TIOTROPIUM | “TIOTROPIUM”, “SPIRIVA” |
| LABA | VILANTEROL | “VILANTEROL”, |
| LAMA | GLYCOPYRRONIUM BROMIDE | |
| LAMA | IPRATROPIUM | “IPRATROPIUM”, |
| THEOPHYLLINE | THEOPHYLLINE | “THEOPHYLLINE”, |
| THEOPHYLLINE | AMINOPHYLLINE | “AMINOPHYLLINE”, “PHYLLOCONTIN” |
| ICS | BECLOMETASONE | “BECLOMETASONE”, |
| ICS | CICLESONIDE | “CICLESONIDE”, “ALVESCO” |
| ICS | BUDESONIDE | “BUDESONIDE”, |
| ICS | FLUTICASONE | “FLUTICASONE”, |
| ICS | MOMETASONE | “MOMETASONE”, |
| LTRA | MONTELUKAST | “MONTELUKAST”, |
| LTRA | ZAFIRLUKAST | “ZAFIRLUKAST”, |
| LTRA | ZILEUTON | “ZILEUTON”, |
| CROMOGLICATE | NEDOCROMIL | “NEDOCROMIL”, |
| CROMOGLICATE | CROMOGLICATE | “CROMOGLICATE”, “CROMOGLYCATE”, |
| STEROID | OMALIZUMAB | “OMALIZUMAB”, |
| STEROID | PREDNISOLONE | “PREDNISOLONE” |
| IMMUNO-SUPPRESSANT | METHOTREXATE | “METHOTREXATE”, |
| IMMUNO-SUPPRESSANT | CICLOSPORIN | “CICLOSPORIN”, |
| IMMUNO-SUPPRESSANT | AZATHIOPRINE | “AZATHIOPRINE”, |
String search keywords may appear under multiple medication and drug class keyword categories, if they contain more than one active ingredient, such as combination ICS LABA medications.
Bold string search keywords indicate brand names.
Exclusion Keywords and Frequency
| Exclusion Keyword | Unique Drug Descriptions ( |
|---|---|
| NASAL | 39 |
| NOSE | 1 |
| NOSTRIL | 0 |
| NASULE | 0 |
| HAYFEVER | 0 |
| EYE | 11 |
| EAR | 0 |
| DROP | 16 |
| TONGUE | 0 |
| FOAM | 2 |
| ENEMA | 1 |
| RECTAL | 0 |
| GASTRO * | 1 |
| MODIFIED * | 0 |
| CREAM | 4 |
| APPLY | 0 |
| SKIN | 0 |
| ULCER | 0 |
| OINTMENT | 6 |
| PATCH | 0 |
| CAPSULE** | 2 |
| SACHET | 0 |
| SPRAY | 33 |
| AZELASTINE | 4 |
| NASONEX | 0 |
| FLIXONASE | 0 |
| ANORA ELLIPTA | 0 |
| SUMATRIPTAN | 0 |
| AVAMYS | 0 |
| RHINOCORT | 0 |
| NASOBEC | 0 |
| NASOFAN | 0 |
| 71 (7.7%) |
* Excluding medications of drug class “steroid” or “theophylline”
** Excluding medications of drug class “steroid”, “theophylline”, “tiotropium” or “glycopyrronium bromide”
Linkage Weight Calculator
| Factor | Criteria | Points | Factor Range | % of candidates | % of matches |
|---|---|---|---|---|---|
| Brand Name * | Both records had non-missing, and distinct, brand names | 0 | 0–20 | 6.3% | 2.8% |
| One or both of the records had a missing brand name | 10 | 0% | 0% | ||
| Both records had non-missing, and matching, brand names | 20 | 93.7% | 97.2% | ||
| (Modified) Dose Strength | Both records had non-missing, and distinct, dose strengths | 0 | 0–35 | 4.8% | 0% |
| One or both of the records had a missing dose strength | 10 | 18.1% | 9.0% | ||
| Both records had non-missing, and matching, dose strengths | 35 | 77.2% | 91.0% | ||
| (Modified) Medication Quantity | Both records had non-missing, and distinct, primary and alias dose quantities | 0 | 0–35 | 4.2% | 0% |
| One or both of the records had a missing primary quantity value, indicating that no value was observed or could be imputed | 10 | 9.8% | < 0.1% | ||
| Both records had non-missing, and distinct, primary dose quantities, but the alias of one record matched to the primary of the other | 15 | 4.9% | 1.5% | ||
| Both records had non-missing, and matching, primary dose quantities | 35 | 81.1% | 98.5% | ||
| Date difference | Dispensing occurred more than one month after prescription (but less than six months) | 0 | 0–10 | 67.2% | 1.3% |
| Dispensing occurred within one month of prescription | 10 | 32.8% | 98.7% |
* If a generic medication was used, the brand name was listed as ‘generic’
Included Feature Weight Combinations
| WEIGHT | BRAND NAME | DOSE STRENGTH | QUANTITY | DATES |
|---|---|---|---|---|
| 100 | Non-missing and matching | Non-missing and matching | Non-missing and matching | Less than one-month delay |
| 90 | One or more missing | Non-missing and matching | Non-missing and matching | Less than one-month delay |
| Non-missing and matching | More than one-month delay | |||
| 80 | Non-missing and distinct | Non-missing and matching | Non-missing and matching | Less than one-month delay |
| Non-missing and matching | Primary/alias match | |||
| One or more missing | Non-missing and matching | More than one-month delay | ||
| 75 | Non-missing and matching | One or more missing | Non-missing and matching | Less than one-month delay |
| Non-missing and matching | One or more missing | |||
| 70 | Non-missing and distinct | Non-missing and matching | Non-missing and matching | More than one-month delay |
| Non-missing and matching | Primary/alias match | |||
| One or more missing | Less than one-month delay |